{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:43:44Z","timestamp":1790322224119,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Amino-bisphosphonates such as zoledronic acid (ZA) can possibly ameliorate or prevent severe COVID-19 disease by at least three distinct mechanisms: (1) as immunostimulants which could boost \u03b3\u03b4 T cell expansion, important in the acute response in the lung; (2) as DC modulators, limiting their ability to only partially activate T cells; and (3) as prenylation inhibitors of small GTPases in the endosomal pathway of the DC to prevent expulsion of lysosomes containing SARS-CoV-2 virions. Use of ZA or other amino-bisphosphonates as modulators of COVID-19 disease should be considered.<\/jats:p>","DOI":"10.1186\/s12967-020-02433-6","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T05:03:40Z","timestamp":1593407020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-7960","authenticated-orcid":false,"given":"Adam","family":"Brufsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis Gomez","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Nasrazadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Lotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"issue":"7","key":"2433_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25(7):829\u201336. https:\/\/doi.org\/10.1200\/JCO.2005.05.3744.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2433_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","volume":"9","author":"AM Brufsky","year":"2009","unstructured":"Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor\u2013associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST Study 36-month follow-up results. Clin Breast Cancer. 2009;9(2):77\u201385. https:\/\/doi.org\/10.3816\/CBC.2009.n.015.","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"2433_CR3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","volume":"15","author":"R Coleman","year":"2014","unstructured":"Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15(9):997\u20131006. https:\/\/doi.org\/10.1016\/S1470-2045(14)70302-X.","journal-title":"Lancet Oncol"},{"issue":"10001","key":"2433_CR4","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(15)60908-4.","journal-title":"Lancet"},{"issue":"4","key":"2433_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00262-012-1368-4","volume":"62","author":"T Sugie","year":"2013","unstructured":"Sugie T, Murata-Hirai K, Iwasaki M, et al. Zoledronic acid-induced expansion of \u03b3\u03b4 T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. Cancer Immunol Immunother. 2013;62(4):677\u201387. https:\/\/doi.org\/10.1007\/s00262-012-1368-4.","journal-title":"Cancer Immunol Immunother"},{"key":"2433_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.trsl.2018.08.005","volume":"203","author":"ES Morrow","year":"2019","unstructured":"Morrow ES, Roseweir A, Edwards J. The role of gamma delta T lymphocytes in breast cancer: a review. Transl Res. 2019;203:88\u201396. https:\/\/doi.org\/10.1016\/j.trsl.2018.08.005.","journal-title":"Transl Res"},{"issue":"1","key":"2433_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00262-008-0521-6","volume":"58","author":"D Santini","year":"2009","unstructured":"Santini D, Martini F, Fratto ME, et al. In vivo effects of zoledronic acid on peripheral \u03b3\u03b4 T lymphocytes in early breast cancer patients. Cancer Immunol Immunother. 2009;58(1):31\u20138. https:\/\/doi.org\/10.1007\/s00262-008-0521-6.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"2433_CR8","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1182\/blood-2011-01-328526","volume":"118","author":"O Nussbaumer","year":"2011","unstructured":"Nussbaumer O, Gruenbacher G, Gander H, Thurnher M. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by \u03b3\u03b4 T lymphocytes. Blood. 2011;118(10):2743\u201351. https:\/\/doi.org\/10.1182\/blood-2011-01-328526.","journal-title":"Blood"},{"issue":"9","key":"2433_CR9","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032\u201345. https:\/\/doi.org\/10.4065\/83.9.1032.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2433_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","volume":"139","author":"RE Hewitt","year":"2005","unstructured":"Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139(1):101\u201311. https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02665.x.","journal-title":"Clin Exp Immunol"},{"issue":"15","key":"2433_CR11","doi-asserted-by":"publisher","first-page":"9388","DOI":"10.1128\/JVI.79.15.9388-9396.2005","volume":"79","author":"AA Dandekar","year":"2005","unstructured":"Dandekar AA, O\u2019Malley K, Perlman S. Important roles for gamma interferon and NKG2D in gammadelta T-cell-induced demyelination in T-cell receptor beta-deficient mice infected with a coronavirus. J Virol. 2005;79(15):9388\u201396. https:\/\/doi.org\/10.1128\/JVI.79.15.9388-9396.2005.","journal-title":"J Virol"},{"issue":"4","key":"2433_CR12","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1084\/jem.183.4.1681","volume":"183","author":"MJ Maeurer","year":"1996","unstructured":"Maeurer MJ, Martin D, Walter W, et al. Human intestinal Vdelta1\u2009+\u2009lymphocytes recognize tumor cells of epithelial origin. J Exp Med. 1996;183(4):1681\u201396. https:\/\/doi.org\/10.1084\/jem.183.4.1681.","journal-title":"J Exp Med"},{"key":"2433_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.coi.2016.06.005","volume":"42","author":"ZW Chen","year":"2016","unstructured":"Chen ZW. Protective immune responses of major V\u03b32\u00a0V\u03b42 T-cell subset in M. tuberculosis infection. Curr Opin Immunol. 2016;42:105\u201312. https:\/\/doi.org\/10.1016\/j.coi.2016.06.005.","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"2433_CR14","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1086\/502975","volume":"193","author":"F Poccia","year":"2006","unstructured":"Poccia F, Agrati C, Castilletti C, et al. Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V\u03b39\u00a0V\u03b42 T Cells. J Infect Dis. 2006;193(9):1244\u20139. https:\/\/doi.org\/10.1086\/502975.","journal-title":"J Infect Dis"},{"issue":"7","key":"2433_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1084\/jem.20110226","volume":"208","author":"W Tu","year":"2011","unstructured":"Tu W, Zheng J, Liu Y, et al. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a \u03b3\u03b4 T cell population in humanized mice. J Exp Med. 2011;208(7):1511\u201322. https:\/\/doi.org\/10.1084\/jem.20110226.","journal-title":"J Exp Med"},{"issue":"10","key":"2433_CR16","doi-asserted-by":"publisher","first-page":"e1000636","DOI":"10.1371\/journal.ppat.1000636","volume":"5","author":"J Zhao","year":"2009","unstructured":"Zhao J, Zhao J, Van Rooijen N, Perlman S. Evasion by stealth: inefficient immune activation underlies poor T Cell response and severe disease in SARS-CoV-Infected Mice. PLoS Pathog. 2009;5(10):e1000636. https:\/\/doi.org\/10.1371\/journal.ppat.1000636.","journal-title":"PLoS Pathog"},{"issue":"5","key":"2433_CR17","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/0008-5472.can-13-0675","volume":"74","author":"H-H Oberg","year":"2014","unstructured":"Oberg H-H, Peipp M, Kellner C, et al. Novel bispecific antibodies increase \u03b3\u03b4 T-cell cytotoxicity against pancreatic cancer cells. Cancer Res. 2014;74(5):1349\u201360. https:\/\/doi.org\/10.1158\/0008-5472.can-13-0675.","journal-title":"Cancer Res"},{"issue":"15","key":"2433_CR18","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/0008-5472.can-07-0199","volume":"67","author":"F Dieli","year":"2007","unstructured":"Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human \u03b3\u03b4 T Cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67(15):7450\u20137. https:\/\/doi.org\/10.1158\/0008-5472.can-07-0199.","journal-title":"Cancer Res"},{"key":"2433_CR19","unstructured":"Kakimi K, Matsushita H, Murakawa T, Nakajima J. \u03b3\u03b4 T cell therapy for the treatment of non-small cell lung cancer. Transl Lung Cancer Res Vol 3, No 1 (February 2014) Transl Lung Cancer Res (Immunotherapy lung cancer-Guest Ed Yasuhiko Nishioka); 2013."},{"issue":"9","key":"2433_CR20","doi-asserted-by":"publisher","first-page":"e1079","DOI":"10.1002\/cti2.1079","volume":"8","author":"S Sant","year":"2019","unstructured":"Sant S, Jenkins MR, Dash P, et al. Human \u03b3\u03b4 T-cell receptor repertoire is shaped by influenza viruses, age and tissue compartmentalisation. Clin Transl Immunol. 2019;8(9):e1079\u2013e1079. https:\/\/doi.org\/10.1002\/cti2.1079.","journal-title":"Clin Transl Immunol"},{"key":"2433_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0944-y","author":"AJ Wilk","year":"2020","unstructured":"Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020. https:\/\/doi.org\/10.1038\/s41591-020-0944-y.","journal-title":"Nat Med"},{"issue":"2","key":"2433_CR22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.immuni.2018.01.009","volume":"48","author":"MR Mamedov","year":"2018","unstructured":"Mamedov MR, Scholzen A, Nair RV, et al. A macrophage colony-stimulating-factor-producing T Cell subset prevents malarial parasitemic recurrence. Immunity. 2018;48(2):350\u201363. https:\/\/doi.org\/10.1016\/j.immuni.2018.01.009.","journal-title":"Immunity"},{"issue":"1","key":"2433_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","volume":"5","author":"L Tan","year":"2020","unstructured":"Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):33. https:\/\/doi.org\/10.1038\/s41392-020-0148-4.","journal-title":"Signal Transduct Target Ther"},{"key":"2433_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.03.20030437","author":"X Chen","year":"2020","unstructured":"Chen X, Ling J, Mo P, et al. Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.03.20030437.","journal-title":"medRxiv."},{"issue":"4","key":"2433_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jmv.25685","volume":"92","author":"G Li","year":"2020","unstructured":"Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424\u201332. https:\/\/doi.org\/10.1002\/jmv.25685.","journal-title":"J Med Virol"},{"key":"2433_CR26","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3575132","author":"X Niu","year":"2020","unstructured":"Niu X, Li S, Li P, et al. Analysis of peripheral blood T Cell receptor and B Cell receptor repertoires reveals dynamic adaptive immune responses in COVID-19 patients. SSRN Electron J. 2020. https:\/\/doi.org\/10.2139\/ssrn.3575132.","journal-title":"SSRN Electron J"},{"key":"2433_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3389\/fphar.2018.00642","volume":"9","author":"Y Tai","year":"2018","unstructured":"Tai Y, Wang Q, Korner H, Zhang L, Wei W. Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. Front Pharmacol. 2018;9:642. https:\/\/doi.org\/10.3389\/fphar.2018.00642.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2433_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/08923970902814103","volume":"31","author":"Y-J Chen","year":"2009","unstructured":"Chen Y-J, Chao KSC, Yang Y-C, Hsu M-L, Lin C-P, Chen Y-Y. Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells. Immunopharmacol Immunotoxicol. 2009;31(3):499\u2013508. https:\/\/doi.org\/10.1080\/08923970902814103.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"8","key":"2433_CR29","doi-asserted-by":"publisher","first-page":"e1021538","DOI":"10.1080\/2162402x.2015.1021538","volume":"4","author":"HH Van Acker","year":"2015","unstructured":"Van Acker HH, Anguille S, Van Tendeloo VF, Lion E. Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy [Internet]. Oncoimmunology. 2015;4(8):e1021538. https:\/\/doi.org\/10.1080\/2162402x.2015.1021538.","journal-title":"Oncoimmunology."},{"issue":"19","key":"2433_CR30","doi-asserted-by":"publisher","first-page":"15961","DOI":"10.1074\/jbc.m008684200","volume":"276","author":"V Lafont","year":"2001","unstructured":"Lafont V, Liautard J, Sable-Teychene M, Sainte-Marie Y, Favero J. Isopentenyl pyrophosphate, a mycobacterial non-peptidic antigen, triggers delayed and highly sustained signaling in human gamma delta T lymphocytes without inducing eown-modulation of T cell antigen receptor. J Biol Chem. 2001;276(19):15961\u20137. https:\/\/doi.org\/10.1074\/jbc.m008684200.","journal-title":"J Biol Chem"},{"key":"2433_CR31","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3389\/fimmu.2018.01246","volume":"9","author":"C Riganti","year":"2018","unstructured":"Riganti C, Castella B, Massaia M. ABCA1, apoA-I, and BTN3A1: a Legitimate M\u00e9nage \u00e0 Trois in Dendritic Cells. Front Immunol. 2018;9:1246.","journal-title":"Front Immunol"},{"issue":"1","key":"2433_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.virusres.2004.09.004","volume":"107","author":"M Yilla","year":"2005","unstructured":"Yilla M, Harcourt BH, Hickman CJ, et al. SARS-coronavirus replication in human peripheral monocytes\/macrophages. Virus Res. 2005;107(1):93\u2013101. https:\/\/doi.org\/10.1016\/j.virusres.2004.09.004.","journal-title":"Virus Res"},{"issue":"MAR","key":"2433_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fimmu.2012.00037","volume":"3","author":"EB Compeer","year":"2012","unstructured":"Compeer EB, Flinsenberg TWH, van Grein SG, Boes M. Antigen processing and remodeling of the endosomal pathway: requirements for antigen cross-presentation. Front Immunol. 2012;3(MAR):37. https:\/\/doi.org\/10.3389\/fimmu.2012.00037.","journal-title":"Front Immunol."},{"issue":"JUN","key":"2433_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fcell.2019.00093","volume":"7","author":"S Kellokumpu","year":"2019","unstructured":"Kellokumpu S. Golgi pH, ion and redox homeostasis: how much do they really matter? Front Cell Dev Biol. 2019;7(JUN):93. https:\/\/doi.org\/10.3389\/fcell.2019.00093.","journal-title":"Front Cell Dev Biol"},{"key":"2433_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/cm9.0000000000000797","volume":"2020","author":"H-H Fan","year":"2019","unstructured":"Fan H-H, Wang L-Q, Liu W-L, et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin Med J (Engl). 2019;2020:1. https:\/\/doi.org\/10.1097\/cm9.0000000000000797.","journal-title":"Chin Med J (Engl)"},{"key":"2433_CR36","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.10.20060558","author":"W Tang","year":"2020","unstructured":"Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. MedRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.10.20060558.","journal-title":"MedRxiv"},{"issue":"12","key":"2433_CR37","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41576-018-0055-5","volume":"19","author":"JL Geoghegan","year":"2018","unstructured":"Geoghegan JL, Holmes EC. The phylogenomics of evolving virus virulence. Nat Rev Genet. 2018;19(12):756\u201369. https:\/\/doi.org\/10.1038\/s41576-018-0055-5.","journal-title":"Nat Rev Genet"},{"issue":"33","key":"2433_CR38","doi-asserted-by":"publisher","first-page":"12540","DOI":"10.1073\/pnas.0605402103","volume":"103","author":"W Lu","year":"2006","unstructured":"Lu W, Zheng B-J, Xu K, et al. Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. Proc Natl Acad Sci. 2006;103(33):12540\u20135. https:\/\/doi.org\/10.1073\/pnas.0605402103.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"2433_CR39","doi-asserted-by":"publisher","first-page":"e02325","DOI":"10.1128\/mBio.02325-17","volume":"9","author":"C Casta\u00f1o-Rodriguez","year":"2018","unstructured":"Casta\u00f1o-Rodriguez C, Honrubia JM, Guti\u00e9rrez-\u00c1lvarez J, et al. Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis. MBio. 2018;9(3):e02325. https:\/\/doi.org\/10.1128\/mBio.02325-17.","journal-title":"MBio"},{"issue":"1","key":"2433_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.antiviral.2011.02.008","volume":"90","author":"S Schwarz","year":"2011","unstructured":"Schwarz S, Wang K, Yu W, Sun B, Schwarz W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res. 2011;90(1):64\u20139. https:\/\/doi.org\/10.1016\/j.antiviral.2011.02.008.","journal-title":"Antiviral Res"},{"key":"2433_CR41","unstructured":"Genomic epidemiology of novel coronavirus - Global subsampling [Internet]. Nextstrain. [cited 2020 Apr 19]; https:\/\/nextstrain.org\/ncov\/global?branchLabel=aa&c=gt-S_614."},{"key":"2433_CR42","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.27.012013","author":"E Issa","year":"2020","unstructured":"Issa E, Merhi G, Panossian B, Salloum T, Tokajian S. SARS-CoV-2 and ORF3a: non-synonymous mutations and polyproline regions. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.27.012013.","journal-title":"bioRxiv"},{"key":"2433_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2286-9","author":"DE Gordon","year":"2020","unstructured":"Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020. https:\/\/doi.org\/10.1038\/s41586-020-2286-9.","journal-title":"Nature"},{"issue":"11","key":"2433_CR44","doi-asserted-by":"publisher","first-page":"e1517","DOI":"10.1038\/cddis.2014.475","volume":"5","author":"S Okamoto","year":"2014","unstructured":"Okamoto S, Jiang Y, Kawamura K, et al. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions. Cell Death Dis. 2014;5(11):e1517\u2013e1517. https:\/\/doi.org\/10.1038\/cddis.2014.475.","journal-title":"Cell Death Dis"},{"issue":"8","key":"2433_CR45","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","volume":"15","author":"FP Coxon","year":"2000","unstructured":"Coxon FP, Helfrich MH, Van Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000;15(8):1467\u201376. https:\/\/doi.org\/10.1359\/jbmr.2000.15.8.1467.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2433_CR46","doi-asserted-by":"publisher","first-page":"a022616","DOI":"10.1101\/cshperspect.a022616","volume":"6","author":"A Wandinger-Ness","year":"2014","unstructured":"Wandinger-Ness A, Zerial M. Rab proteins and the compartmentalization of the endosomal system. Cold Spring Harb Perspect Biol. 2014;6(11):a022616. https:\/\/doi.org\/10.1101\/cshperspect.a022616.","journal-title":"Cold Spring Harb Perspect Biol."},{"issue":"10","key":"2433_CR47","doi-asserted-by":"publisher","first-page":"e0165004","DOI":"10.1371\/journal.pone.0165004","volume":"11","author":"E Puissant","year":"2016","unstructured":"Puissant E, Boonen M. Monocytes\/macrophages upregulate the hyaluronidase HYAL1 and adapt its subcellular trafficking to promote extracellular residency upon differentiation into osteoclasts. PLoS ONE. 2016;11(10):e0165004\u2013e0165004. https:\/\/doi.org\/10.1371\/journal.pone.0165004.","journal-title":"PLoS ONE"},{"issue":"3","key":"2433_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4161\/sgtp.2.3.16453","volume":"2","author":"C Itzstein","year":"2011","unstructured":"Itzstein C, Coxon FP, Rogers MJ. The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases. 2011;2(3):117\u201330. https:\/\/doi.org\/10.4161\/sgtp.2.3.16453.","journal-title":"Small GTPases"},{"issue":"6","key":"2433_CR49","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.stemcr.2015.04.012","volume":"4","author":"Y Xiao","year":"2015","unstructured":"Xiao Y, Zijl S, Wang L, et al. Identification of the common origins of osteoclasts, macrophages, and dendritic cells in human hematopoiesis. Stem cell reports. 2015;4(6):984\u201394. https:\/\/doi.org\/10.1016\/j.stemcr.2015.04.012.","journal-title":"Stem cell reports"},{"issue":"13","key":"2433_CR50","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1182\/blood-2008-01-132787","volume":"112","author":"A Wakkach","year":"2008","unstructured":"Wakkach A, Mansour A, Dacquin R, et al. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood. 2008;112(13):5074\u201383. https:\/\/doi.org\/10.1182\/blood-2008-01-132787.","journal-title":"Blood"},{"key":"2433_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2015.11.004","volume":"82","author":"O-C Jeon","year":"2016","unstructured":"Jeon O-C, Seo D-H, Kim H-S, Byun Y, Park JW. Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: In vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats. Eur J Pharm Sci. 2016;82:1\u201310. https:\/\/doi.org\/10.1016\/j.ejps.2015.11.004.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"2433_CR52","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood.V96.2.384","volume":"96","author":"V Kunzmann","year":"2000","unstructured":"Kunzmann V, Bauer E, Feurle J, Tony Hans-Peter FW, Wilhelm M. Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96(2):384\u201392. https:\/\/doi.org\/10.1182\/blood.V96.2.384.","journal-title":"Blood"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02433-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-020-02433-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02433-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T20:07:04Z","timestamp":1624910824000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02433-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2433"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02433-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"4 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB is a paid consultant for Novartis, Amgen, and Sandoz. MTL, JG, and AR have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}